Results from two recent phase 3 clinical trials show risankizumab significantly improved the skin and joint symptoms of patients with psoriatic arthritis compared with placebo.

Results from two recent phase 3 clinical trials show risankizumab significantly improved the skin and joint symptoms of patients with psoriatic arthritis compared with placebo.
Bradley Bohman, MD, & Jawad Bilal, MBBS |
Tumor necrosis factor-α inhibitors (TNFi’s) have emerged as an integral part of therapeutic strategies for several rheumatic diseases. TNF-α is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis (RA), seronegative spondyloarthropathies and inflammatory bowel disease (IBD). It also plays a central role in the immune response to mycobacterial infection. Many biologic agents, particularly…
Abdollah Shams-Pirzadeh, MD, PA, FACR, & Kimberly Retzlaff |
Humans are not perfectly symmetrical. Almost everyone has one ear that’s higher or one foot that’s larger than the other. Similarly, leg lengths are often not quite the same. There is disagreement as to what constitutes a clinically significant difference, but some studies suggest that leg length discrepancy (LLD) can lead to osteoarthritis (OA) of…
Tamar Rubinstein, MD, Natoshia Cunningham, PhD, & Andrea Knight, MD, MSCE |
It is nine months into the COVID-19 pandemic in the U.S. and the third wave is upon us, overwhelming hospital systems in many states across the country. But the alarms are being sounded for another looming pandemic as well. As early as spring 2020, significant increases were documented in the prevalence of depression and anxiety,…
A recent pilot study explores the feasibility of virtual reality-based pain interventions for people with rheumatic conÂditions.1 Although the work is in its early stages, it may someday represent a new non-pharmacological tool for patients with chronic pain. VR for Treatment R. Swamy Venuturupalli, MD, FACR, is an associate clinical professor of medicine at the…
Hanan Ibrahim, MD, Weixia Guo, MD, & Ayad Alkhatib, MD |
Reactive arthritis is classically associated with an infectious etiology, such as Salmonella, Yersinia, Campylobacter, Chlamydia or gonorrhea. Clostridium difficile is a rare, and recently recognized, causative agent for this condition.1 Case Presentation The patient is a 21-year-old man with a past medical history significant for hereditary spherocytosis and Crohn’s disease, complicated by an anorectal fistula,…
Leonard H. Calabrese, DO |
Rheumatology has arguably benefited like no other field from the proliferation of an increasingly effective pipeline of therapeutics. These medications have dramatically raised the bar for clinical outcomes for our patients in a way that we could not have envisioned a short generation ago. With such therapeutic progress now reaching a widening circle of rheumatic…
As the new chair of the Registries & Health Information Technology Committee, William F. Harvey, MD, MSc, hopes to expand representation of patient diversity in the RISE registry and increase the use of registry data for research.
Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.